AAV-mediated exon skipping therapy for Usher syndrome, type 2A.
Mauriac SA, Lee J, Zhang J, Jin J, Nist-Lund C, Martin CT, Von Muhlenbrock CR, O'Malley S, Chaves MG, Madison MA, Foster K, Long S, Jacobs C, Kumar SR, Ramirez S, Ichida J, Koehler KR, Holt JR, Géléoc GSG.
Mauriac SA, et al. Among authors: nist lund c.
Mol Ther. 2026 Jan 7;34(1):179-202. doi: 10.1016/j.ymthe.2025.09.038. Epub 2025 Sep 23.
Mol Ther. 2026.
PMID: 40994011